Blue Cross and Blue Shield of Alabama continues to support the health, safety and well-being of its members and has taken comprehensive steps to ensure they have access to the health care they need during the pandemic. This includes providing coverage for the latest therapies, including the FDA-authorized COVID-19 monoclonal antibody treatment.
The U.S. Food and Drug Administration recently expanded its Emergency Use Authorization allowing providers to prescribe REGEN-COV for the treatment of COVID-19 as well as prevention in some individuals who are at high risk of severe disease. According to the FDA, monoclonal antibody treatment is recommended for those with mild to moderate COVID symptoms. This can also include adults and children over 12 years of age and weighing at least 88 pounds who are exposed and at a high risk for severe COVID-19, including hospitalization and death. Monoclonal antibody therapy is covered at 100% with no member cost share as a preventive measure for those who are eligible and as their benefits apply.
Health experts say treatment should start quickly after being diagnosed with COVID-19 and within the first 10 days of when symptoms started. Talk to your provider if you think you may be eligible for treatment.
Alabamians can help end the pandemic by getting the vaccine, wearing face masks, practicing social distancing and washing hands often.
For more information on COVID-19 and the Delta Variant go to www.cdc.gov/coronavirus.
Don’t miss out! Subscribe today to have Alabama’s leading headlines delivered to your inbox.